Lundbeckfonden
Lundbeckfonden is an independent non-profit private foundation based in Copenhagen, Denmark, established in 1954 by Grete Lundbeck. Its main objective is to maintain and expand the activities of the Lundbeck Group while providing financial support for research in biomedical and natural sciences. The foundation operates through several investment arms, including Lundbeckfonden Emerge and Lundbeckfond Ventures. Lundbeckfonden Emerge focuses on seed, startup, and early-stage investments in companies with high intellectual property potential, actively engaging in project development alongside founders. It aims to transform scientific discoveries into commercially viable ventures, offering both financing and strategic guidance. Lundbeckfond Ventures, on the other hand, is an evergreen life science venture fund that invests up to €50 million annually, adopting a long-term investment perspective to generate returns that support the foundation's broader activities while remaining independent from the Lundbeck Group's ownership interests.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Snipr Biome ApS, founded in 2017 and based in Copenhagen, Denmark, is a biotechnology company focused on developing innovative treatments for microbial diseases using CRISPR technology. The company aims to revolutionize healthcare by employing a programmable approach to target and eliminate harmful bacteria in vivo. By leveraging the adaptive immune system, Snipr Biome's therapies selectively identify and kill bacteria based on their specific DNA sequences. This targeted strategy provides healthcare professionals with advanced options for microbiome engineering, enhancing the precision and efficacy of treatments for bacterial infections.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.